Effectiveness of omalizumab therapy in patients with highly severe allergic asthma treated in Department of Pulmonology in Krakow

Immunoglobulin E plays an important role in allergic diseases. In patients with allergic asthma, exposure to allergens releases a wide range of proinflamatory mediators, which are responsible for acute and chronic symptoms of the disease. IgE has become an attractive target in allergic asthma. In 2006, in Europe omalizumab became available.